CEO Ming Hsieh highlighted year-over-year growth in the laboratory services segment and momentum in 2025. The company's therapeutic development pipeline progresses with FID-007 in Phase 2 trials for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback